Clinical Pediatric Emergency Medicine
Volume 6, Issue 2 , Pages 93-102 , June 2005

Drug Interactions—A Review

  • Shannon F. Manzi, PharmD

      Affiliations

    • Emergency Department Clinical Pharmacist, Children's Hospital Boston, Boston, MA 02115, USA
    • Northeastern University, Boston, MA 02115, USA
    • Corresponding Author InformationReprint requests and correspondence: Shannon F. Manzi, PharmD, Department of Pharmacy, Children's Hospital Boston, 300 Longwood Ave, Boston, MA 02115.
    • ,
  • Michael Shannon, MD, MPH

      Affiliations

    • Division of Emergency Medicine, Children's Hospital Boston, Boston, MA 02115, USA
    • Harvard Medical School, Boston, MA 02115, USA

References 

  1. Linnarsson R. Drug interactions in primary health care. A retrospective database study and its implications for the design of a computerized decision support system. Scand J Prim Health Care. 1993;11:181–186
  2. Monaghan MS, Falls L, Olsen KM. Potential drug interactions with H2-receptor antagonists in intensive care unit patients. Hosp Pharm 1993;28:296-297, 300-305.
  3. Gaddis GM, Holt TR, Woods M. Drug interactions in at-risk emergency department patients. Acad Emerg Med. 2002;9:1162–1167
  4. Wallace AW, Victory JM, Amsden GW. Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers. J Clin Pharmacol. 2003;43:539–544
  5. In: Pfizer Labs. p. Vibramycin package insert.
  6. Neuhofel AL, Wilton JH, Victory JM, et al. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol. 2002;42:461–466
  7. Kato R, Ueno K, Imano H, et al. Impairment of ciprofloxacin absorption by calcium polycarbophil. J Clin Pharmacol. 2002;42:806–811
  8. Wallace AW, Victory JM, Amsden GW. Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers. J Clin Pharmacol. 2003;43:92–96
  9. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology. 1982;32:570–572
  10. Faraji B, Yu PP. Serum phenytoin levels of patients on gastrostomy tube feeding. J Neurosci Nurs. 1998;30:55–59
  11. Maynard GA, Jones KM, Guidry JR. Phenytoin absorption from tube feedings. Arch Intern Med. 1987;147:1821
  12. Rodman DP, Stevenson TL, Ray TR. Phenytoin malabsorption after jejunostomy tube delivery. Pharmacotherapy. 1995;15:801–805
  13. Saklad JJ, Graves RH, Sharp WP. Interaction of oral phenytoin with enteral feedings. JPEN J Parenter Enteral Nutr. 1986;10:322–323
  14. Sneed RC, Morgan WT. Interference of oral phenytoin absorption by enteral tube feedings. Arch Phys Med Rehabil. 1988;69:682–684
  15. La Humma YL. Pharmacogenetics. In:  Dipiro JT editors. Pharmacotherapy, a pathophysiologic approach. 5th ed.. New York (NY): McGraw Hill; 2002;p. 55–67
  16. Gheuens J. Propulsid—Important drug warning. Janssen Pharmaceutica Research Foundation; 2000;
  17. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121:676–683
  18. Drug input and disposition. In: Mark H, Beers RB, editors. The Merck manual of diagnosis and therapy. 17th ed. Medical Services, USMEDSA, USHH; 2004.
  19. Shannon M. Drug-drug interactions and the cytochrome P450 system: an update. Pediatr Emerg Care. 1997;13:350–353
  20. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–1167
  21. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529–537
  22. Alscher DM, Klotz U. Drug interaction of herbal tea containing St. John's wort with cyclosporine. Transpl Int. 2003;16:543–544
  23. Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St. John's wort and cyclosporine. Ann Pharmacother. 2000;34:1013–1016
  24. Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation. 2001;71:239–241
  25. Breidenbach T, Kliem V, Burg M, et al. Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum). Transplantation. 2000;69:2229–2230
  26. Izzo AA. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther. 2004;42:139–148
  27. Karliova M, Treichel U, Malago M, et al. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol. 2000;33:853–855
  28. Markowitz JS, DeVane CL. The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum). Psychopharmacol Bull. 2001;35:53–64
  29. Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. Am J Kidney Dis. 2001;38:1105–1107
  30. Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev. 2003;35:35–98
  31. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev. 2004;36:57–104
  32. Cuzzolin L, Zaffani S, Murgia V, et al. Patterns and perceptions of complementary/alternative medicine among paediatricians and patients' mothers: a review of the literature. Eur J Pediatr. 2003;162:820–827
  33. Lanski SL, Greenwald M, Perkins A, Simon HK. Herbal therapy use in a pediatric emergency department population: expect the unexpected. Pediatrics. 2003;111:981–985
  34. Noonan K, Arensman RM, Hoover JD. Herbal medication use in the pediatric surgical patient. J Pediatr Surg. 2004;39:500–503
  35. Wilkinson G. Pharmacokinetics. In:  Hardman JG,  Limbird LE,  Gillman AG editor. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed.. New York (NY): McGraw Hill; 2001;
  36. Hazai E, Vereczkey L, Monostory K. Reduction of toxic metabolite formation of acetaminophen. Biochem Biophys Res Commun. 2002;291:1089–1094
  37. Watson Laboratories I. Probenicid package insert. 2003.
  38. Beorlegui B, Aldaz A, Ortega A, et al. Potential interaction between methotrexate and omeprazole. Ann Pharmacother. 2000;34:1024–1027
  39. Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol. 1993;33:82–84
  40. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–551
  41. Scott G. Spironolactone for heart failure: balancing benefit and risk in pharmacist's letter. Stockton (CA): Therapeutic Research Center; 2004;
  42. Svensson M, Gustafsson F, Galatius S, et al. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ. 2003;327:1141–1142
  43. Wrenger E, Muller R, Moesenthin M, et al. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003;327:147–149
  44. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351:585–592
  45. McMurray JJ, O'Meara E. Treatment of heart failure with spironolactone—trial and tribulations. N Engl J Med. 2004;35:526–528
  46. Baldessarini R. Drugs and the treatment of psychiatric disorders. In:  Hardman JG,  Limbird LE,  Gillman AG editor. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed.. New York (NY): McGraw Hill; 2001;
  47. Rose LM, Ohlinger MJ, Mauro VF. A hypertensive reaction induced by concurrent use of selegiline and dopamine. Ann Pharmacother. 2000;34:1020–1024
  48. Aga VM, Barklage NE, Jefferson JW. Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants. J Clin Psychiatry. 2003;64:609–611
  49. French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51:ii45–ii53
  50. Hammerness P, Parada H, Abrams A. Linezolid: MAOI activity and potential drug interactions. Psychosomatics. 2002;43:248–249
  51. Hendershot PE, Antal EJ, Welshman IR, et al. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J Clin Pharmacol. 2001;41:563–572
  52. Thomas CR, Rosenberg M, Blythe V, Meyer WJ. Serotonin syndrome and linezolid. J Am Acad Child Adolesc Psychiatry. 2004;43:790
  53. Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997;33:454–471
  54. Kehoe W. Update on adverse reactions to SSRI antidepressants. In: Pharmacist's letter. Stockton (CA): Therapeutic Research Center; 1998;
  55. Muscettola G, Pampallona S, Barbato G, et al. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand. 1993;87:29–36

PII: S1522-8401(05)00056-X

doi: 10.1016/j.cpem.2005.04.006

Clinical Pediatric Emergency Medicine
Volume 6, Issue 2 , Pages 93-102 , June 2005

Article Tools